Daewoo Pharmaceutical Ind. Co., Ltd.

Sung-Uk Chung

Dong-Hee Kim

Young-Hoon Ji

Jae-Seon Kang

Sung-Woo Hwang

Kyung-Ran Kang

Jung-Ae Kim

Chun-Gyu Kim

You-Ra Kang

The present invention relates to an anti-inflammatory use of macrolactin compounds such as macrolactin A, 7-O-malonyl macrolactin A and 7-O-succinyl macrolactin A, which are produced from a novelstrain ofKJS-2 (KCCM10769P). The macrolactin compounds provided by the present invention were confirmed to greatly suppress the expression and formation of inducible nitric oxide synthetase (iNOS) and cyclooxygenase-2 (COX-2) which are proteins related to the formation of inflammatory mediators, and to accordingly inhibit the formation of nitric oxide (NO) and of prostaglandin E2 (PGE2) which are the metabolites of the proteins. In addition, the macrolactin compounds provided by the present invention were confirmed to have excellent effects in inhibiting the formation of tumor necrosis factor-alpha (TNF-&#x3b1;), interleukin-1&#x3b2; (IL-1&#x3b2;), interleukin-6 (IL-6) and granulocyte macrophage colony-stimulating factor (GM-CSF), which are pro-inflammatory cytokines. Therefore, the macrolactin compounds produced by theKJS-2 strain according to the present invention can provide excellent anti-inflammatory agents.

Anti-inflammatory composition containing macrolactin A and a derivative thereof as active ingredients

The present invention relates to an anti-angiogenic composition containing macrolactin compounds such as macrolactin A, 7-O-malonyl macrolactin A, and 7-O-succinyl macrolactin A as active ingredients. The macrolactin compounds according to the present invention strongly suppress angiogenesis in in vivo experiments and can be used as a pharmaceutical composition for preventing or treating diseases caused by angiogenesis.

Anti-angiogenic composition containing macrolactin A and a derivative thereof as active ingredients

Growing community of inventors

Seoul, South Korea

Sung-Uk Chung